Literature DB >> 12201846

Immunological characterization of anti-Mi(a), a red blood cell alloantibody, in Taiwan.

S-C Lo1, J-S Chang, S W-S Lin, D-T Lin.   

Abstract

BACKGROUND AND OBJECTIVES: The red blood cell Mi III phenotype is prevalent in Asia, and its corresponding alloantibody, anti-Mi(a), has been reported to cause haemolytic transfusion reactions and haemolytic disease of the newborn. However, a complete picture of the immunological characteristics of anti-Mi(a) is still lacking. We therefore conducted a systematic study to evaluate the potential clinical significance of this antibody.
MATERIALS AND METHODS: From April 1999 to March 2000, we identified 60 sera containing anti-Mi(a) among pretransfusion samples at a teaching hospital in Taiwan. These antibodies were tested for immunoglobulin class, thermal range and activity in a monocyte monolayer assay.
RESULTS: Thirty-four (57%) of the antibodies were immunoglobulin M (IgM), and 15 retained their activity at 37 degrees C. Of those that were immunoglobulin G (IgG), 96% were of subclasses IgG1 and/or IgG3. Monocyte monolayer assay studies showed that 69% (18/26) of the IgG anti-Mi(a) sera were reactive.
CONCLUSIONS: Our study justifies the implementation of anti-Mi(a) screening in Taiwan.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12201846     DOI: 10.1046/j.1423-0410.2002.00212.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  2 in total

1.  Red blood cell alloimmunisation among Chinese patients with β-thalassaemia major in Taiwan.

Authors:  Yu-Hua Chao; Kang-Hsi Wu; Jang-Jih Lu; Mu-Chin Shih; Ching-Tien Peng; Ci-Wen Chang
Journal:  Blood Transfus       Date:  2012-06-28       Impact factor: 3.443

2.  Identification and Quantification of Anti-Gp.Mur Antibodies in Human Serum Using an Insect-Cell-Based System.

Authors:  Robert John S Lamis; Tsong-Shi Chiueh; Chih-Hsuan Tsai; Huei-Ru Lo; Sung-Chan Wei; Yu-Chan Chao
Journal:  Diagnostics (Basel)       Date:  2021-05-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.